Edgar Filing: CTI BIOPHARMA CORP - Form 4

	ARMA CORP										
Form 4	5 2015										
September 2	_										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB	PROVAL 3235-0287		
Check th	nis box		Wa	shington,	, D.C. 20	549			Number:	January 31,	
if no lon	- NIATHA	IENT OI	F CHAN	IGES IN	BENEF	ICIA	LOWN	ERSHIP OF	Expires:	2005	
subject t Section Form 4 o	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							nated average en hours per onse 0.5			
Form 5 obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17(a) of the 1	Public U		ding Con	npany	Act of 1	Act of 1934, 1935 or Section			
(Print or Type	Responses)										
SINGER JACK W Symbo			Symbol	suer Name and Ticker or Trading ol BIOPHARMA CORP [ctic]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (1	Middle)	3. Date o	f Earliest Transaction				(Check all applicable)			
				/Day/Year) 2015				X Director 10% Owner X Officer (give title Other (specify below) below) EVP, Global Medical Affairs			
	(Street)		4. If Ame	endment, Date Original				6. Individual or Joint/Group Filing(Check			
SEATTLE,	WA 98121		Filed(Mo	nth/Day/Yea	r)			Applicable Line) _X_ Form filed by O Form filed by M	ne Reporting Pe	rson	
							I	Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities Acqui	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	Code (Instr. 8)	oror Dispose (Instr. 3, 4	ed of (and 5 (A) or	D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6.7. Nature of IndirectOwnershipIndirectForm:BeneficialDirect (D)Ownershipor Indirect(Instr. 4)(I)(Instr. 4)		
Common	09/25/2015			Code V S(1)	Amount 1,300	(D) D	Price \$ 1.63	1,465,550	D		
Stock				_	,			,,			
Common Stock	09/25/2015			S <u>(1)</u>	400	D	\$ 1.6325	1,465,150	D		
Common Stock	09/25/2015			S <u>(1)</u>	100	D	\$ 1.635	1,465,050	D		
Common Stock	09/25/2015			S <u>(1)</u>	13,200	D	\$ 1.64	1,451,850	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	of			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SINGER JACK W 3101 WESTERN AVE SUITE 600 SEATTLE, WA 98121	Х		EVP, Global Medical Affairs				
Signatures							
By: Louis A. Bianco, Attorney Singer	09/25/2015						

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Date